乳腺癌的表观遗传修饰:从免疫逃生机制到治疗点发现
Ziyu Kang1, Junlin Wang2, Jiyan Liu3
1Institute of Chinese Medical Literature and Culture, Shandong University of Chinese Medicine, Jinan, China.
Frontiers in immunology
|May 2, 2025
概括
表观遗传修饰在乳腺癌 (BC) 的发展和瘤免疫微环境 (TIME) 中发挥着至关重要的作用. 了解这些表观遗传标记为BC早期检测和个性化治疗提供了新的途径.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 乳腺癌 (BC) 是全球领先的女性癌症,由于免疫逃避,复发和药物耐药性,其发病率和治疗挑战日益增加.
- 表观遗传学,包括DNA甲基化,基因组修饰,染色质结构和非编码RNA,对于理解癌症的发展至关重要.
- 表观遗传标记物对早期BC检测和个性化治疗策略有希望.
研究的目的:
- 综合审查表观遗传修饰在乳腺癌发展中的作用.
- 总结一下表观遗传修饰如何影响BC.的瘤免疫微环境 (TIME).
- 以突出基于表观遗传机制的新型诊断和治疗点.
主要方法:
- 文献综述专注于乳腺癌中的表观遗传机制.
- 对调查表观遗传学与瘤免疫微环境之间的联系的研究进行分析.
- 对表观遗传抑制剂及其治疗潜力的当前研究进行综合.
主要成果:
- 表观遗传改变是BC开始和进展的基本驱动因素.
- 表观遗传修饰显著塑造了BC瘤免疫微环境,影响了免疫逃避.
- 表观遗传向药物在各种癌症中表现出有效性,改善了患者的生存率和生活质量.
结论:
- 表观遗传修饰是了解BC病原和时间的关键.
- 针对表观遗传机制为BC诊断和治疗提供了新的视角.
- 整合多omics数据将推进乳腺癌的精准医学.
更多相关视频
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
11.2K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
4.8K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Epigenetic Regulation
2.9K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
2.9K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Tumor Immunotherapy
397
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397
